Quick Answer
Galmed Pharmaceuticals Ltd. reported Cash and Equivalents of $3.98 million for fiscal year 2025.
Galmed Pharmaceuticals Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.98M | -14.3% |
| 2024 | $4.65M | +62.6% |
| 2023 | $2.86M | +41.9% |
| 2022 | $2.02M | -30.1% |
| 2021 | $2.88M | -58.5% |
| 2020 | $6.95M | -56.4% |
| 2019 | $15.93M | -34.1% |
| 2018 | $24.16M | +85.5% |
| 2017 | $13.02M | +320.4% |
| 2016 | $3.10M | -25.5% |
| 2015 | $4.16M | -82.5% |
| 2014 | $23.74M | +17225.5% |
| 2013 | $137.0K | -80.9% |
| 2012 | $718.0K | +391.8% |
| 2011 | $146.0K | — |
- Galmed Pharmaceuticals Ltd. showed a decrease of -14.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Galmed Pharmaceuticals Ltd.’s cash and equivalents has grown by 2629.5% (from $146.0 thousand to $3.98 million).
- The most recent figure is from Galmed Pharmaceuticals Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: